ALZHEIMER’S BLOOD TEST AIDS EARLY DETECTION BUT LIMITATIONS

Why in the News?

A blood test for Alzheimer’s disease biomarkers, already cleared in the U.S. and available in India, can detect biological changes linked to the disease. However, experts caution that it is not a general screening test, particularly for people without symptoms.

Science Behind Alzheimer’s Detection and Blood Test

●     Neural disruption: Alzheimer’s progressively damages communication between the brain’s nearly 86 billion neurons, affecting memory, thinking and speech as neuronal connections deteriorate.

●     Amyloid stage: The disease begins with accumulation of misfolded beta-amyloid protein, forming plaques between brain cells, often more than a decade before noticeable memory problems.

●     Tau stage: Later, tau protein develops abnormal tangles inside neurons, eventually causing neuronal death and driving clinical deterioration.

●     Biomarker detection: The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio measures two blood biomarkers reflecting these brain changes.

●     Biological signals: As amyloid accumulates, β-amyloid 1-42 decreases, while pTau 217 increases as tau pathology develops. Their ratio helps indicate Alzheimer’s-related pathology.

●     Diagnostic potential: The test showed high agreement with amyloid PET scans and cerebrospinal-fluid tests in specialist settings, supporting its potential as a less-invasive diagnostic aid.

Clinical Use: Benefits, Risks and Limitations

●     Target population: The test is intended for adults over 50 years presenting with cognitive decline in specialised care, rather than healthy individuals seeking routine screening.

●     Therapeutic requirement: Before anti-amyloid treatment, confirmed amyloid pathology is required to establish that the patient is an appropriate candidate.

●     False positives: Real-world evidence indicates that the test may identify amyloid-positive results among people who ultimately do not have the pathology, creating concerns about false-positive findings.

●     Psychological impact: Testing asymptomatic individuals could produce premature anxiety and medicalisation, especially when preventive treatment evidence remains limited.

●     Better prevention: For people without symptoms, emphasis remains on blood-pressure control, physical activity, adequate sleep, hearing care, and social and cognitive engagement.

●     Clinical judgement: Therefore, the blood test should complement specialist assessment, rather than replace clinical evaluation or function as a stand-alone diagnostic or population-wide screening tool.

 About Alzheimer’s Disease and Biomarker-Based Diagnosis:

●     Neurodegenerative disorder: Alzheimer’s is a progressive neurodegenerative disease involving deterioration of neurons and cognitive functions, particularly memory and reasoning.

●     Disease biomarkers: Amyloid plaques and tau tangles are major pathological hallmarks used to identify Alzheimer’s disease biologically.

●     Traditional diagnosis: Assessment generally combines cognitive testing, clinical history and brain imaging, while also excluding conditions such as stroke or tumours that can produce similar symptoms.

●     Blood advantage: Biomarker-based blood testing could provide a less invasive and more accessible alternative to procedures such as cerebrospinal-fluid analysis or expensive imaging.

●     Early intervention: Early identification has gained importance because newer anti-amyloid therapies, including donanemab and lecanemab, can slow progression in selected patients when used during early disease stages.